- Home
- NJR vs LEGN Comparison
NJR vs LEGN Comparison
Compare NJR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NJR
- LEGN
- Stock Information
- Founded
- NJR 1922
- LEGN 2014
- Country
- NJR United States
- LEGN United States
- Employees
- NJR N/A
- LEGN N/A
- Industry
- NJR Oil/Gas Transmission
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- NJR Utilities
- LEGN Health Care
- Exchange
- NJR Nasdaq
- LEGN Nasdaq
- Market Cap
- NJR 4.6B
- LEGN 5.4B
- IPO Year
- NJR N/A
- LEGN 2020
- Fundamental
- Price
- NJR $47.91
- LEGN $35.56
- Analyst Decision
- NJR Hold
- LEGN Strong Buy
- Analyst Count
- NJR 6
- LEGN 10
- Target Price
- NJR $51.50
- LEGN $73.67
- AVG Volume (30 Days)
- NJR 611.8K
- LEGN 1.1M
- Earning Date
- NJR 08-04-2025
- LEGN 08-11-2025
- Dividend Yield
- NJR 3.76%
- LEGN N/A
- EPS Growth
- NJR 72.02
- LEGN N/A
- EPS
- NJR 4.10
- LEGN N/A
- Revenue
- NJR $2,096,114,000.00
- LEGN $796,838,000.00
- Revenue This Year
- NJR $9.27
- LEGN $66.76
- Revenue Next Year
- NJR $2.24
- LEGN $52.58
- P/E Ratio
- NJR $11.67
- LEGN N/A
- Revenue Growth
- NJR 21.02
- LEGN 74.75
- 52 Week Low
- NJR $43.80
- LEGN $27.34
- 52 Week High
- NJR $51.95
- LEGN $59.62
- Technical
- Relative Strength Index (RSI)
- NJR 63.33
- LEGN 35.54
- Support Level
- NJR $46.20
- LEGN $35.10
- Resistance Level
- NJR $47.59
- LEGN $38.35
- Average True Range (ATR)
- NJR 0.71
- LEGN 1.31
- MACD
- NJR 0.02
- LEGN -0.37
- Stochastic Oscillator
- NJR 96.17
- LEGN 11.33
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.